Literature DB >> 7910884

HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.

I Loussert-Ajaka1, T D Ly, M L Chaix, D Ingrand, S Saragosti, A M Couroucé, F Brun-Vézinet, F Simon.   

Abstract

Nine patients with atypical HIV-1 western blot profiles were diagnosed as having HIV-1 subtype O infection. All the patients were living in France; eight originated from Cameroon and one from France. Lymphocyte DNA amplification by the polymerase chain reaction was only positive when HIV-1 subtype O specific primers were used. Preliminary sequence analysis of amplified products and serological reactivity against a specific subtype O synthetic env peptide confirmed HIV-1 subtype O infection. HIV-1/HIV-2 enzyme-linked immunosorbent assays, especially those based on env peptides or on the sandwich format, can be negative in HIV-1 subtype O infection.

Entities:  

Mesh:

Year:  1994        PMID: 7910884     DOI: 10.1016/s0140-6736(94)92524-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5.

Authors:  A Holguín; B Aracil; A Alvarez; C Barros; V Soriano
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

4.  Integrating laboratory and epidemiological techniques for population-based surveillance of HIV strains and drug resistance in Canada.

Authors:  G C Jayaraman; C P Archibald; L Lior; D Sutherland
Journal:  Can J Infect Dis       Date:  2000-03

5.  Multicenter evaluation of new double-antigen sandwich enzyme immunoassay for measurement of anti-human immunodeficiency virus type 1 and type 2 antibodies.

Authors:  P Burgisser; F Simon; M Wernli; T Wust; M F Beya; P C Frei
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

6.  First case of HIV-1 subtype 0 infection in Germany.

Authors:  H Hampl; D Sawitzky; M Stöffler-Meilicke; A Groh; M Schmitt; J Eberle; L Gürtler
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

7.  Simultaneous visual detection of multiple viral amplicons by dipstick assay.

Authors:  Magda Anastassova Dineva; Daniel Candotti; Fiona Fletcher-Brown; Jean-Pierre Allain; Helen Lee
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Authors:  Mohan Kumar Haleyur Giri Setty; Jikun Liu; Prerna Mahtani; Panhe Zhang; Bingchen Du; Viswanath Ragupathy; Krishnakumar Devadas; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

9.  Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections.

Authors:  J-C Plantier; M Djemai; V Lemée; A Reggiani; M Leoz; L Burc; A Vessière; D Rousset; J-D Poveda; C Henquell; A Gautheret-Dejean; F Barin
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

10.  Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon.

Authors:  Avelin F Aghokeng; Eitel Mpoudi-Ngole; Henriette Dimodi; Arrah Atem-Tambe; Marcel Tongo; Christelle Butel; Eric Delaporte; Martine Peeters
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.